Literature DB >> 22929873

Cognitive enhancement in schizophrenia: pharmacological and cognitive remediation approaches.

Philip D Harvey1, Christopher R Bowie.   

Abstract

This article discusses the measurement of cognition in schizophrenia, its role as a determinant of disability, and treatment efforts to date, including pharmacological and behavioral interventions as well as effective treatments that lead to improved outcomes. The measurement of functioning when patients with schizophrenia receive treatment in the office is addressed. The review focuses on new developments in the creation and adoption of a consensus method for the assessment of cognitive functioning in treatment studies, on the increased appreciation for assessment of functional skills in the prediction of everyday outcomes, and on developments in the basic neuroscience of cognition.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22929873      PMCID： PMC3430871          DOI： 10.1016/j.psc.2012.06.008

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN： 0193-953X


  66 in total

1.  Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment.

Authors:  T Sumiyoshi; M Matsui; S Nohara; I Yamashita; M Kurachi; C Sumiyoshi; K Jayathilake; H Y Meltzer
Journal:  Am J Psychiatry       Date:  2001-10       Impact factor: 18.112

2.  UCSD Performance-Based Skills Assessment: development of a new measure of everyday functioning for severely mentally ill adults.

Authors:  T L Patterson; S Goldman; C L McKibbin; T Hughs; D V Jeste
Journal:  Schizophr Bull       Date:  2001       Impact factor: 9.306

3.  Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial.

Authors:  Douglas L Boggs; Deanna L Kelly; Robert P McMahon; James M Gold; David A Gorelick; Jared Linthicum; Robert R Conley; Fang Liu; James Waltz; Marilyn A Huestis; Robert W Buchanan
Journal:  Schizophr Res       Date:  2011-12-03       Impact factor: 4.939

4.  Maldistribution of interstitial neurons in prefrontal white matter of the brains of schizophrenic patients.

Authors:  S Akbarian; J J Kim; S G Potkin; W P Hetrick; W E Bunney; E G Jones
Journal:  Arch Gen Psychiatry       Date:  1996-05

5.  Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial.

Authors:  Richard S E Keefe; Sophia Vinogradov; Alice Medalia; Peter F Buckley; Stanley N Caroff; Deepak C D'Souza; Phillip D Harvey; Karen A Graham; Robert M Hamer; Stephen M Marder; Del D Miller; Stephen J Olson; Jayendra K Patel; Dawn Velligan; Trina M Walker; Adam J Haim; T Scott Stroup
Journal:  J Clin Psychiatry       Date:  2012-05-15       Impact factor: 4.384

6.  Psychosis and brain volume changes during the first five years of schizophrenia.

Authors:  W Cahn; M Rais; F P Stigter; N E M van Haren; E Caspers; H E Hulshoff Pol; Z Xu; H G Schnack; R S Kahn
Journal:  Eur Neuropsychopharmacol       Date:  2008-12-03       Impact factor: 4.600

7.  A placebo-controlled add-on trial of the Ampakine, CX516, for cognitive deficits in schizophrenia.

Authors:  Donald C Goff; J Steven Lamberti; Andrew C Leon; Michael F Green; Alexander L Miller; Jayendra Patel; Theo Manschreck; Oliver Freudenreich; Steven A Johnson
Journal:  Neuropsychopharmacology       Date:  2007-05-09       Impact factor: 7.853

8.  Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials.

Authors:  Donald C Goff; Richard Keefe; Leslie Citrome; Katherine Davy; John H Krystal; Charles Large; Thomas R Thompson; Jan Volavka; Elizabeth L Webster
Journal:  J Clin Psychopharmacol       Date:  2007-12       Impact factor: 3.153

9.  The MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization.

Authors:  Robert S Kern; Keith H Nuechterlein; Michael F Green; Lyle E Baade; Wayne S Fenton; James M Gold; Richard S E Keefe; Raquelle Mesholam-Gately; Jim Mintz; Larry J Seidman; Ellen Stover; Stephen R Marder
Journal:  Am J Psychiatry       Date:  2008-01-02       Impact factor: 18.112

10.  Effects on the brain of a psychological treatment: cognitive remediation therapy: functional magnetic resonance imaging in schizophrenia.

Authors:  Til Wykes; Michael Brammer; John Mellers; Peter Bray; Clare Reeder; Clare Williams; Julia Corner
Journal:  Br J Psychiatry       Date:  2002-08       Impact factor: 9.319
View more
  15 in total

1.  Severity of hypertension predicts the generalized neurocognitive deficit in schizophrenia.

Authors:  Lindsay F Morra; Gregory P Strauss
Journal:  Schizophr Res       Date:  2016-07-07       Impact factor: 4.939

Review 2.  Oxytocin and social cognition in affective and psychotic disorders.

Authors:  M Mercedes Perez-Rodriguez; Katie Mahon; Manuela Russo; Allison K Ungar; Katherine E Burdick
Journal:  Eur Neuropsychopharmacol       Date:  2014-08-01       Impact factor: 4.600

3.  Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo.

Authors:  Lone Baandrup; Birgitte Fagerlund; Birte Glenthoj
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-07-11       Impact factor: 5.270

Review 4.  Psychopharmacological treatment of neurocognitive deficits in people with schizophrenia: a review of old and new targets.

Authors:  Anthony O Ahmed; Ishrat A Bhat
Journal:  CNS Drugs       Date:  2014-04       Impact factor: 5.749

5.  Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models.

Authors:  Holly Moore; Mark A Geyer; Cameron S Carter; Deanna M Barch
Journal:  Neurosci Biobehav Rev       Date:  2013-09-30       Impact factor: 8.989

6.  Social cognition, social competence, negative symptoms and social outcomes: Inter-relationships in people with schizophrenia.

Authors:  Marc Kalin; Sara Kaplan; Felicia Gould; Amy E Pinkham; David L Penn; Philip D Harvey
Journal:  J Psychiatr Res       Date:  2015-07-13       Impact factor: 4.791

7.  The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.

Authors:  Douglas L Boggs; Toral Surti; Aarti Gupta; Swapnil Gupta; Mark Niciu; Brian Pittman; Ashley M Schnakenberg Martin; Halle Thurnauer; Andrew Davies; Deepak C D'Souza; Mohini Ranganathan
Journal:  Psychopharmacology (Berl)       Date:  2018-04-05       Impact factor: 4.530

8.  EEG reveals that dextroamphetamine improves cognitive control through multiple processes in healthy participants.

Authors:  Savita G Bhakta; James F Cavanagh; Jo A Talledo; Juliana E Kotz; Lindsay Benster; Benjamin Z Roberts; John A Nungaray; Jonathan L Brigman; Gregory A Light; Neal R Swerdlow; Jared W Young
Journal:  Neuropsychopharmacology       Date:  2022-01-18       Impact factor: 8.294

9.  Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study.

Authors:  Veena Kumari; Ulrich Ettinger; Seoung Eun Lee; Christine Deuschl; Anantha P Anilkumar; Anne Schmechtig; Philip J Corr; Dominic H Ffytche; Steven C R Williams
Journal:  Psychopharmacology (Berl)       Date:  2015-05-19       Impact factor: 4.530

Review 10.  Prediction of treatment outcomes in psychiatry--where do we stand ?

Authors:  Francis J McMahon
Journal:  Dialogues Clin Neurosci       Date:  2014-12       Impact factor: 5.986
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.